EPO Patents = 6

Forward Citations = 13

Loading Chart...

8 inventors (with patents filed for the assignee):

John Charles Reader (7 out of 19 patents)

John Mark Ellard (2 out of 3 patents)

Helen Boffey (2 out of 2 patents)

4. Susanne Taylor (2 out of 2 patents)

5. Andrew David Carr (2 out of 2 patents)

6. Michael Cherry (2 out of 10 patents)

7. Michelle Wilson (2 out of 2 patents)

8. Richard Boakye Owoare (2 out of 5 patents)

7 patents: Sort by Forward Citations

1. 12187716 - TYK2 kinase inhibitors (2025-01-07),

2. 11673870 - Pharmaceutical compounds (2023-06-13),

3. 11154539 - Pharmaceutical compounds (2021-10-26),

4. 10882829 - Pharmaceutical compounds (2021-01-05),

5. 9187465 - Oxazole tyrosine kinase inhibitors (2015-11-17),

6. 9133180 - Aurora and FLT3 kinases modulators (2015-09-15),

7. 8921544 - Oxazole tyrosine kinase inhibitors (2014-12-30),

Sareum is a drug discovery and development company, focused on small molecule therapeutics for the treatment of cancer. Their unique approach involves the use of structure-based drug design to create targeted therapies that have the potential to improve patient outcomes. With a strong pipeline of novel drug candidates in various stages of development, Sareum is committed to advancing cutting-edge treatments for cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 13 2026

7 Patents

#116 in Cambridge

#2,300 in United Kingdom

Cambridge, United Kingdom

Sareum Limited